Multiple Sclerosis Drugs Market Size $34.36 Billion by 2030
Report Overview:
The Global Multiple Sclerosis Drugs Market achieved a valuation of $25.90 Billion in 2022 and is anticipated to exceed $34.36 Billion by 2030, reflecting a compounded annual growth rate (CAGR) of 3.6% during the forecast period from 2024 to 2032.
Key Market Players:
Celgene Corporation, Acorda Therapeutics Inc., Biogen Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG., Sanofi, F. Hoffmann-La Roche Ltd. and others.